Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) EBIT Margin (2023 - 2025)

Tonix Pharmaceuticals Holding has reported EBIT Margin over the past 3 years, most recently at 895.84% for Q4 2025.

  • Quarterly results put EBIT Margin at 895.84% for Q4 2025, down 2520.0% from a year ago — trailing twelve months through Dec 2025 was 959.05% (up 39523.0% YoY), and the annual figure for FY2025 was 959.05%, up 39523.0%.
  • EBIT Margin for Q4 2025 was 895.84% at Tonix Pharmaceuticals Holding, up from 1005.08% in the prior quarter.
  • Over the last five years, EBIT Margin for TNXP hit a ceiling of 551.17% in Q3 2024 and a floor of 3501.63% in Q2 2024.
  • Median EBIT Margin over the past 3 years was 860.23% (2024), compared with a mean of 1091.72%.
  • Biggest five-year swings in EBIT Margin: plummeted -268329bps in 2024 and later surged 208541bps in 2025.
  • Tonix Pharmaceuticals Holding's EBIT Margin stood at 723.18% in 2023, then fell by -20bps to 870.64% in 2024, then dropped by -3bps to 895.84% in 2025.
  • The last three reported values for EBIT Margin were 895.84% (Q4 2025), 1005.08% (Q3 2025), and 1416.22% (Q2 2025) per Business Quant data.